Thrombocytopenia associated with the use of anti-tumor necrosis factor-α agents for psoriasis

Journal of the American Academy of Dermatology

Volumn 60, Issue 5, 2009, Pages 781-785

  Brunasso, Alexandra Maria Giovanna ^a,b   Massone, Cesare ^c  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

adalimumab; efalizumab; etanercept; infliximab; psoriasis; thrombocytopenia

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DEXAMETHASONE; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RELAPSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PSORIASIS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64749084123     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.12.001     Document Type: Article

References (25)

1. Nevitt G.J., and Hutchinson P.E. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 135 (1996) 533-537
2. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
3. Day R. Adverse reactions to TNF-alpha blockers in rheumatoid arthritis. Lancet 359 (2002) 540-541
4. Warkentin T.E., and Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 143 (2005) 761-763
5. Pathare S.K., Heycock C., and Hamilton J. TNF alpha blocker-induced thrombocytopenia. Rheumatology 45 (2006) 1313-1314
6. Salar A., Bessa X., Muñiz E., Monfort D., Besses C., and Andreu M. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Gut 56 (2007) 1169-1170
7. Gerloni V., Pontikaki I., Gattinara M., and Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 67 (2008) 1145-1152
8. Feletar M., Brockbank J.E., Schentag C.T., Lapp V., and Gladman D.D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63 (2004) 156-161
9. Stinco G., Piccirillo F., and Patrone P. Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis. Acta Derm Venereol 88 (2008) 281-282
10. Hamaguchi M., Kawahito Y., Ishino H., Yoshida M., and Yoshikawa T. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol 26 (2007) 988-990
11. Vidal F., Fontova R., and Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139 (2003) W62-W63
12. Driessen R.J., Berends M.A., Boezeman J.B., van de Kerkhof P.C., and de Jong E.M. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol 158 (2008) 1098-1106
13. Menon Y., Cucurull E., and Espinoza R. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology 42 (2003) 1273-1274
14. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 42 (1999) 1785-1796
15. George J.N., Raskob G.E., Shah S.R., Rizvi M.A., Hamilton S.A., Osborne S., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129 (1998) 886-890
16. Neylon A.J., Saunders P.W.G., Howard M.R., Proctor S.J., and Taylor P.R.A. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 122 (2003) 966-974
17. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., and Nakanishi A.M. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
18. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double blind trial. Lancet 366 (2005) 1367-1374
19. Visentin G.P., and Liu C.Y. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 21 (2007) 685-696
20. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
21. Via C.S., Shustov A., Rus V., Lang T., Nguyen P., and Finkelman F.D. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167 (2001) 6821-6826
22. McDevitt H., Munson S., Ettinger R., and Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 4 Suppl 3 (2002) S141-S152
23. Litton G. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept. Am J Hematol 83 (2008) 344
24. McMinn Jr. J.R., Cohen S., Moore J., Lilly S., Parkhurst J., Tarantino M.D., et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 73 (2003) 135-140
25. Lazaraki G., Metallidis S., Giannoulis K., Tarpagos A., and Germanidis G. Infliximab: an alternative treatment for refractory immune thrombocytopenic purpura related to Crohn's disease?. Inflamm Bowel Dis 13 (2007) 1452-1453